Android app on Google Play

Jefferies Upgrades Infinity Pharmaceutical (INFI) to Buy

May 7, 2014 6:40 AM EDT Send to a Friend
Get Alerts INFI Hot Sheet
Price: $9.90 +1.02%

Rating Summary:
    9 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 9 | New: 24
Trade INFI Now!
Join SI Premium – FREE

Jefferies upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Hold to Buy with a price target of $13.00 (from $15.00) citing attractive risk/reward.

Analyst Eun K. Yang, Ph.D commented, "Our concerns for INFI have been commercial competitiveness of IPI-145 in a rapidly evolving market. However, at current EV of ~$265M (>70% down from 52-wk high), such concerns are largely priced in for active product IPI-145 (likely clinical success). Thus, ahead of pivotal Ph2/3 data in r/r iNHL/CLL in ~2Q/3Q15, we view risk/rewards as attractive; upgrading to Buy."

The firm bumped FY 2014 EPS from ($3.40) to ($3.28) while cutting FY 2015 EPS from ($1.88) to ($2.01).

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $9.05 yesterday.





You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Hot Upgrades, Upgrades

Related Entities

Jefferies & Co

Add Your Comment